Humaneered™ Technology Platform
KaloBios’ patented proprietary Humaneered™ technology platform is designed to address problems of antibody engineering (e.g., specificity, affinity, immunogenicity, etc.), but also equally important Down Stream Processing (DSP) issues of antibody R&D (e.g., solubility, expression, aggregation, etc.). The process is fast and produces antibodies close to human germ-line in sequence while retaining the specificity and improving the affinity of the reference antibody. Humaneering has now been tested clinically and to date no anti-drug antibodies have been detected even in healthy volunteers.
- Engineered human
- Low/No immunogenicity
- Rapid
- Equal or higher affinity than starting antibody
- Solves antibody problems:
- Aggregation
- Stability
- Expression level (in both mammalian and microbial systems)
- Binding kinetics (select for Ka vs. Kd)
Click here to see the system deployed for KaloBios’ Humaneered™ technology
This novel system allows a true alternative to classic antibody engineering technologies, bringing a cost advantage to our pipeline as well as the opportunity to provide service to others.
This novel system allows a true alternative to classic antibody engineering technologies, bringing a cost advantage to our pipeline as well as the opportunity to provide service to others. KaloBios also offers Humaneered™ research and development services to companies developing new pharmaceutical products.